Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM4 | Q14833 | 1/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.31 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.30 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.30 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.30 |
| ▸ | APLNR | P35414 | 1/20 | 0.30 |
| ▸ | PDCD1 | Q15116 | 2/20 | 0.30 |
| ▸ | CD274 | Q9NZQ7 | 2/20 | 0.30 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27102702 | 0.80 | CCNB2 (0.36) | GRM4DYRK1ACYP3A4CYP2D6SLC6A2 | |
| SCHEMBL18544284 | 0.78 | GRM4 (0.34) | GRM4DYRK1ALRRK2CYP3A4CYP2D6 | |
| SCHEMBL21321500 | 0.75 | LRRK2 (0.33) | GRM4DYRK1ALRRK2APLNRNFE2L2 | |
| SCHEMBL23620231 | 0.67 | CCNB2 (0.36) | LRRK2CYP2D6APLNR | |
| SCHEMBL21376391 | 0.67 | ALDH1A1 (0.37) | CYP3A4CYP2D6 | |
| SCHEMBL14853043 | 0.67 | CCR1 (0.39) | DYRK1ALRRK2APLNR | |
| SCHEMBL21848988 | 0.66 | CD274 (0.36) | CYP3A4CYP2D6SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL27102704 | 0.66 | TLR9 (0.36) | CYP3A4CYP2D6APLNR | |
| SCHEMBL21563189 | 0.66 | CSNK2A1 (0.36) | DYRK1ALRRK2CYP3A4CYP2D6APLNR | |
| SCHEMBL25829653 | 0.66 | TRPA1 (0.38) | DYRK1ALRRK2CYP3A4CYP2D6APLNR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10364254-B2 | Compounds for use in antibacterial applications | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-07-30 | — | — | US | disclosed |
| US-20190031680-A1 | COMPOUNDS FOR US IN ANTIBACTERIAL APPLICATIONS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190031680-A1 | COMPOUNDS FOR US IN ANTIBACTERIAL APPLICATIONS | CFTR, MRPL21, CLPP | GRM4 4662/4885DYRK1A 2854/4885LRRK2 1504/4885 |
| US-10364254-B2 | Compounds for use in antibacterial applications | MRPL21, CFTR, NRDC | GRM4 4640/4885DYRK1A 3414/4885LRRK2 1633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.